Navigation Links
Micromet Reports Fourth Quarter and Full Year 2009 Financial Results
Date:3/4/2010

noclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com.

Safe Harbor Statement

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the development and commercialization of blinatumomab, MT110 and other BiTE antibodies, including the conduct and timing of ongoing and future clinical trials involving these product candidates, the manufacturing of blinatumomab, as well as plans regarding our regulatory strategy and announcements and publication of clinical data. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ m
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Data from Phase 1 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Non-Hodgkins Lymphoma
2. Micromet, Inc. Reports Second Quarter 2009 Financial Results
3. Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203
4. Micromet, Inc. Reports First Quarter 2009 Financial Results
5. Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference
6. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting
7. Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference
8. Micromet, Inc. Reports Second Quarter 2008 Financial Results
9. Micromet, Inc. Reports First Quarter 2008 Financial Results
10. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
11. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Parker Waichman LLP, a ... of victims injured by defective medical devices, reports ... allegations that the woman’s hidden, aggressive leiomyosarcoma was ... used during a routine laparoscopic supracervical hysterectomy procedure. ... Medical Instruments Corporation over its Wolf Power Morcellator ...
(Date:7/10/2014)... record becomes widespread across the United States, due in ... the quantity of clinical data that will become available ... Additionally, experts in healthcare have become increasingly focused ... for the purpose of gleaning insights that have the ... a process that is known as big data. ...
(Date:7/10/2014)... with dyslexia are more likely to report that they ... who don,t have the learning disorder, according to a ... 10 percent of people, causes problems with reading and ... this condition said they suffered physical abuse during their ... "Even after accounting for age, race, sex and ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Men who have ... prostate cancer, a new study suggests. But the ... urologists not involved with the study said more research ... truly accurate. For the study, Harvard researchers analyzed ... followed for 24 years, starting in 1986. During that ...
(Date:7/10/2014)... 10, 2014In response to today,s announcement that the "Mississippi ... has now been found to have detectable levels of ... expresses disappointment in this setback but remains hopeful that ... to remain undetectable for more than two years will ... and ultimately develop a cure. , "Although we ...
Breaking Medicine News(10 mins):Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Despite setback, 'Mississippi Baby' represents significant breakthrough in effort to end AIDS 2
... donations is spiraling for older couples wanting to start ... ... shifts in parenting,trends have fertility experts at Reproductive Endocrinology Associates of,Charlotte (REACH) ... 2008 -- including new outreach through the Internet --,in efforts to stem ...
... Patent Expands Geographic Coverage, IRVING, ... (OTC Bulletin Board: CARN) today announced ... patent application No. 200600484, titled,"Delivery of ... Anionic,Polysaccharides," relating to the Company,s proprietary ...
... Professor of Epidemiology and Associate Dean for Health Promotion ... of Medicine, and Virginia A. Stallings, MD, PhD, the ... Penn and Professor of Pediatrics at The Childrens Hospital ... a special public session, Understanding Obesity and Childhood at ...
... Nationally in, March 2008 Tells the Story of Six ... Mountain in the Himalayas with Blind Climber ... Entertainment and Junior,Blind of America announced today that from ... (opening March,2008) will travel to the United States for ...
... the Way to Educating Children With Food,Allergies, FAIRFAX, ... (FAAN) is proud to announce the release of two ... allergies.,Alexander, the Elephant Who Couldn,t Eat Peanuts ... Goes ... ... Gets a Babysitter help,children cope with their own ...
... Progress in Women,s Cancer, Theme, Spotlights Four ... Cancers, CHICAGO, Feb. 11 The Society ... Meeting on Women,s Cancer March,9-12 at the Tampa ... will feature more than 350 scientific presentations,lectures, workshops, ...
Cached Medicine News:Health News:Charlotte IVF Experts Issue Urgent Call for Egg Donors, Eye New Recruiting Tools 2Health News:Carrington's DelSite Drug Delivery Technology Granted Patent From Eurasian Patent Office 2Health News:Carrington's DelSite Drug Delivery Technology Granted Patent From Eurasian Patent Office 3Health News:Blind Tibetan Teenagers Featured in Award-Winning Film, 'Blindsight,' Unite with Students from Junior Blind of America to Share Life Experiences 2Health News:Blind Tibetan Teenagers Featured in Award-Winning Film, 'Blindsight,' Unite with Students from Junior Blind of America to Share Life Experiences 3Health News:New Alexander, the Elephant Who Couldn't Eat Peanuts DVDs Help Children With Food Allergies 2Health News:New Alexander, the Elephant Who Couldn't Eat Peanuts DVDs Help Children With Food Allergies 3Health News:Society of Gynecologic Oncologists to Host 39th Annual Meeting on Women's Cancer 2Health News:Society of Gynecologic Oncologists to Host 39th Annual Meeting on Women's Cancer 3
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Every Bard BrachyStar® Needle is designed ... an efficient and clinically effective brachytherapy procedure. ... featuring ultra-sharp tips and polished surfaces for ... of needle configurations and sizes assures an ...
... The BrachySource iodine-125 implant is a combination ... remarkable visibility that makes BrachySource I-125 implant ... You can be confident that every BrachySource ... seed management services which is required by ...
... implant is a combination of innovative design, ... makes TheraSeed® treatment an ideal choice for ... that every TheraSeed® implant order is backed ... required by clinicians who must meet the ...
... Used for temporary internal drainage from the ... of a stricture. The segment with no ... lumen while preventing ingrowth of the ureteral ... peel-open packages. Intended for one-time use. CAUTION: ...
Medicine Products: